There are several barriers to wider access to genomic testing in Europe.
Lack of value
recognition
The value of advanced diagnostics is not sufficiently recognized.
Funding is insufficient and support not well suited to increase their role in the clinical setting.
The time to market for advanced diagnostics is too long, complex, and fraught with uncertainty.
There is a lack of pathways to appraisal that are time-bound and flexible and that can accommodate the unique characteristics of advanced diagnostics.
Essential clinical supporting infrastructure—including appropriately trained workforce, data sharing and data storage infrastructure capabilities, and digital health recording within healthcare systems—is lacking in Europe.
Out of the 279 genetics and genomics companies worldwide, over 63% (176) are currently based
in the US, compared with 21% located in Europe
Percentage of genomics companies by location (region/country)
Time to
market delays
Lack of
infrastructure
